Savara/$SVRA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Savara
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
- Ticker
- $SVRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 70
- Headquarters
- Yardley, United States
- Website
- www.savarapharma.com
Savara Metrics
BasicAdvanced
$1.1B
-
-$0.58
0.25
-
Price and volume
Market cap
$1.1B
Beta
0.25
52-week high
$7.01
52-week low
$3.86
Average daily volume
2.4M
Financial strength
Current ratio
10.132
Quick ratio
9.994
Long term debt to equity
0.21
Total debt to equity
0.212
Profitability
EBITDA (TTM)
-142.699
Management effectiveness
Return on assets (TTM)
-50.15%
Return on equity (TTM)
-105.48%
Valuation
Price to book
7.46
Price to tangible book (TTM)
8.1
Price to free cash flow (TTM)
-9.189
Free cash flow yield (TTM)
-10.88%
Free cash flow per share (TTM)
-0.459
Growth
Earnings per share change (TTM)
12.69%
3-year earnings per share growth (CAGR)
29.01%
What the Analysts think about Savara
Analyst ratings (Buy, Hold, Sell) for Savara stock.
Analyst projections of the future price of Savara stock.
Bulls say / Bears say
In Phase 3 IMPALA-2, molgramostim improved exercise capacity versus placebo: patients walked an estimated 80.6 metres farther and exercised one minute longer at week 48. Both differences were statistically significant, adding functional evidence to the treatment’s case. (Savara Inc.)
Longer-term trial follow-up showed continued improvement in lung function and respiratory quality of life, with 94% of patients retained through the first 48 weeks of the open-label extension. No patients discontinued that period because of treatment-related side effects, supporting the prospect of sustained use. (Savara Inc.)
Savara’s drug is under review in the US, UK and EU, with an FDA action date set for 22 November 2026 and European and UK decisions expected later. The company says there are no approved medicines for autoimmune PAP, so approval could give it a first-mover position in an unmet-need market. (Savara Inc., Savara Inc.)
The FDA extended its review by three months after deciding Savara’s response to information requests amounted to a major amendment. The agency did not cite specific safety or efficacy concerns, but the extra review time leaves approval and launch timing uncertain. (SEC)
Savara reported a $40.2 million quarterly loss and $173 million in cash and short-term investments at June 2026, down from $235.7 million at year-end 2025. The additional capital it says may be available after approval is conditional, leaving the company exposed to continued cash use if approval or launch is delayed. (Savara Inc.)
Savara sought to double its authorised common shares to 600 million and expand its incentive-plan share pool. That would give the company more room to issue shares, creating a potential dilution risk as it funds a commercial launch. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
Savara Financial Performance
Revenues and expenses
Savara Earnings Performance
Company profitability
Upcoming events
No upcoming events
Savara News
AllArticlesVideos
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Business Wire3 days ago
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Business Wire2 weeks ago
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Business Wire2 months ago
Funds containing Savara
Fund name | Fund size | $SVRA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.